Stylus Medicine, Inc. (“Stylus”), a biotechnology company dedicated to developing transformative in vivo genetic medicines, emerges from stealth with $85 million in financing. Stylus’ funding includes a $45 million Series A extension financing with participation from RA Capital Management, Khosla Ventures, and six new investors including Chugai Venture Fund, Eli Lilly and Company, and Johnson & Johnson Innovation – JJDC. This financing follows a $40 million Series A investment from founding investors RA Capital and Khosla Ventures.
Stylus will use this financing to advance its in vivo genetic medicines platform and pipeline of in vivo therapeutic programs. The company’s powerful and elegant engineering platform combines sequence-specific genome integration with cell-targeted lipid nanoparticle (LNP) delivery. The platform is based on Stylus-designed therapeutic-grade recombinases capable of encoding polyfunctional multi-kb payloads with high efficiency, high specificity, and high fidelity. This system enables durable, flexible, and scalable in vivo cell engineering, overcoming major limitations of ex vivo cell therapy manufacturing and expanding the reach of transformative genetic medicines.
“Stylus was established to reimagine how genetic medicines reach patients. At the core of our approach are three defining features of an ideal therapy: safe and targeted in vivo delivery, specific integration, and durable expression of a therapeutic payload,” said Emile Nuwaysir, Ph.D., Chairman and Chief Executive Officer of Stylus. “By removing the complexity of ex vivo and viral manufacturing, we will dramatically simplify patient treatment. Our goal is to bring the life-saving promise of genetic medicines to every patient in need, starting with CAR-T therapies.”
“Stylus was created in 2022 by Raven, RA Capital’s healthcare incubator, and Khosla Ventures to solve the fundamental challenges holding back genetic medicines,” said Joshua Resnick, M.D., Partner at RA Capital and President of Raven. “The Stylus system is incredibly elegant, and Stylus has the right team, capital, and strategy to succeed. The company has the potential to vastly expand the availability of life-changing therapies, while creating a scalable, efficient model that is attractive from both a clinical and commercial perspective.”